Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03521323|
Recruitment Status : Recruiting
First Posted : May 10, 2018
Last Update Posted : May 10, 2018
This study aim to evaluate the safety and efficacy of intrathecal transplantation of allogeneic umbilical cord derived mesenchymal stem cells (UC-MSC) for treatment of different phrases of spinal cord injury. Here, the history of spinal cord injury is divided into three periods, Sub-acute SCI, Early stage of chronic SCI, and Late stage of chronic SCI, which is 2W-2M, 2M-12M, and more than 12M after injury, respectively. The purpose is to investigate whether the patients with spinal cord injury benefit from UC-MSC transplantation, and then find out the best time for SCI treatment.
In this part of the study, the investigators will treat patients with early stage of chronic spinal cord injury with UC-MSC transplantation or placebo.
|Condition or disease||Intervention/treatment||Phase|
|Spinal Cord Injuries||Drug: Umbilical Cord Mesenchymal Stem Cells Drug: Placebos||Phase 2|
Spinal cord injury (SCI), damage to any part of the spinal cord or nerves, often causes permanent neurofunction deficit, including strength, sensation and other body functions below the site of injury. WHO reported 15-40/million people suffer from SCI each year, about 250,000 to 500,000 people. The majority of SCI victims are young patients, who are at the time of working age. As a result of that, SCI not only affects the physical and psychological health of those patients, but also bring huge economic burden to their families, as well as the society. The current treatments for SCI mainly include surgical operation, neuroregenerative medicine, physical therapy, chinese acupuncture and so on. However, none of these methods are efficient enough to make any functional recovery of neurological injury in patients, and most patients will have to face paraplegia or tetraplegia.
The most challenge of SCI treatment are reported to be regeneration of axon and rewiring of the damaged spinal cord. The properties of strong proliferation and differentiation make stem cell transplantation possible to replace the damage axon and rebridge the injury spinal cord. Currently, evidences from animal experiments and pilot clinical studies have reported that umbilical cord mesenchymal stem cells transplantation was a potential method to treat spinal cord injury, but its safety and efficacy remain controversial.
This study will conduct a multicenter, randomized, controlled trial for UC-MSC transplantation for the treatment of different phrases of SCI, including sub-acute, early stage, and late stage of chronic SCI. These three trials will investigate the safety and efficacy of intrathecal transplantation of UC-MSC in patients with SCI treatment. The study will be conducted at 3 hospitals in China, covering eastern, southern and western of Chinese mainland.
The primary outcome is the changes of motor and sensory assessment before and after intervention using American Spinal Injury Association (ASIA) Score Scale. Secondary outcomes will include International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS), electromyogram test, residual urine test and adverse events.
The enrolled participants will be followed up at baseline, 1, 3, 6 and 12 months after UC-MSC transplantation. Besides, the samples of serum and cerebrospinal fluid will be collected, before and after treatment, to explore the potential mechanism of UC-MSC transplantation for the treatment of SCI.
The results of this study will, for the first time, provide high level of evidence as to the relative safety and efficacy of UC-MSC transplantation for the treatment of spinal cord injury.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||92 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial|
|Actual Study Start Date :||January 1, 2018|
|Estimated Primary Completion Date :||December 30, 2022|
|Estimated Study Completion Date :||December 30, 2022|
Experimental: Umbilical Cord Mesenchymal Stem Cells
Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
Drug: Umbilical Cord Mesenchymal Stem Cells
Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
Other Name: UC-MSC
Placebo Comparator: Control
Sham operation and 10ml saline as placebos, once a month for 4 months
Placebos: Saline，Sham operation
Other Name: Sham operation
- Changes in American Spinal Injury Association (ASIA) Score Scale [ Time Frame: Baseline, 1 month, 3 months, 6 months and 12 months post-treatment ]Changes in motor and sensory scores assessed by the ASIA score scale (total score range from 0 to 324, higher values represent a better outcome)
- Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS) [ Time Frame: Baseline, 1 month, 3 months, 6 months and 12 months post-treatment ]Changes in motor and sensory scores assessed by IANR-SCIRFS scale (total score range from 0 to 51, higher values represent a better outcome)
- Changes in electromyogram test [ Time Frame: Baseline, 6 months and 12 months post-treatment ]Changes in electromyogram test
- Changes in residual urine [ Time Frame: Baseline, 6 months and 12 months post-treatment ]Changes in residual urine measured by ultrasound test (volume of urine in mL, lower values represent a better outcome)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03521323
|Contact: Limin Rong, M.D.||email@example.com|
|Contact: Liangming Zhang, M.D.||firstname.lastname@example.org|
|The Third Affiliated Hospital, Sun Yat-Sen University||Recruiting|
|Guangzhou, Guangdong, China, 510630|
|Contact: Limin Rong, M.D. 8620-85252900 email@example.com|
|Principal Investigator:||Limin Rong, M.D.||Sun Yat-sen University|